Epidermal growth factor receptor inhibitors

The present invention relates to novel compounds of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, which have EGFR inhibitor properties, to pharmaceutical compositions containing said compounds, to methods of treating diseases or disorders and the use of said compou...

Full description

Saved in:
Bibliographic Details
Main Authors SMETANIN, ILIA ALEXEEVICH, KHAIDAROV, ADEL RAVILEVICH, POLIANCZYK, DANIEL EVGENEVICH, STARODUBTSEVA, RAMILIA RINADOVNA, MOROZOV, DMITRY VALENTINOVICH, IAKOBSON, GEORGII VIKTOROVICH, BEKETOVA, DARIA DMITRIEVNA, SUNTSOVA, POLINA OLEGOVNA, KHALABUDIN, DMITRY ALEKSEEVICH, ZAVIALOV, KIRILL VADIMOVICH, KADYROV, SHAMIL DINAROVICH, SHEKHAUTSOU, ARTSIOM EVGENIEVICH
Format Patent
LanguageChinese
English
Published 01.11.2022
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to novel compounds of formula I: or pharmaceutically acceptable salt, solvate or stereoisomer thereof, which have EGFR inhibitor properties, to pharmaceutical compositions containing said compounds, to methods of treating diseases or disorders and the use of said compounds as pharmaceutical products for treating diseases or disorders.
Bibliography:Application Number: TW202110149610